Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIHCC: TACE + Arginine + Trimetazidine in HCC
NCT03274427Phase 3Unknown
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Jul 2017
- Primary completion
- Jul 2021
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of arginine and trimetazidine in hepatocellular carcinoma (HCC) (3 arms), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: Progression-free Survival at 24 months. Status: unknown.
02
Drugs
argininetrimetazidine
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03274427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03274427.